id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-D-5473-0029,FDA,FDA-2019-D-5473,"Promotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Biosimilar Products, and Interchangeable Biosimilar Products Questions and Answers Guidance for Industry",Other,Guidance,2025-12-10T05:00:00Z,2025,12,2025-12-10T05:00:00Z,,2025-12-10T20:21:24Z,,1,0,09000064b90c20c5
FDA-2019-D-5473-0028,FDA,FDA-2019-D-5473,"Promotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Biosimilar Products, and Interchangeable Biosimilar Products: Questions and Answers; Guidance for Industry; Availability",Notice,Notice of Availability,2025-12-10T05:00:00Z,2025,12,,,2025-12-10T20:21:09Z,2025-22427,0,0,09000064b90c159b
FDA-2019-D-5473-0016,FDA,FDA-2019-D-5473,"Promotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Biosimilar Products, and Interchangeable Biosimilar Products: Questions and Answers; Revised Draft Guidance for Industry; Availability",Notice,Notice of Availability,2024-04-25T04:00:00Z,2024,4,,,2024-04-25T13:30:21Z,2024-08886,0,0,09000064864ee605
FDA-2019-D-5473-0017,FDA,FDA-2019-D-5473,"Promotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Biosimilar Products, and Interchangeable Biosimilar Products Questions and Answers Guidance for Industry; Revised Draft Guidance",Other,Guidance,2024-04-25T04:00:00Z,2024,4,2024-04-25T04:00:00Z,2024-06-25T03:59:59Z,2025-12-10T20:21:36Z,,0,0,09000064864ee8bc
FDA-2019-D-5473-0002,FDA,FDA-2019-D-5473,"Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products Questions and Answers
Guidance for Industry",Other,Guidance,2020-02-04T05:00:00Z,2020,2,2020-02-04T05:00:00Z,2020-04-07T03:59:59Z,2024-04-25T13:29:55Z,,0,0,0900006484325d68
FDA-2019-D-5473-0001,FDA,FDA-2019-D-5473,"Promotional Labeling and Advertising Considerations for Prescription
Biological Reference and Biosimilar Products—Questions and Answers;
Draft Guidance for Industry; Availability",Notice,Notice of Availability,2020-02-04T05:00:00Z,2020,2,2020-02-04T05:00:00Z,2020-04-07T03:59:59Z,2020-02-23T21:50:39Z,2020-02100,0,0,0900006484325636